Resistance · Health Care · Pharmaceuticals
The history of penicillin resistance
Resistance to penicillin is not a late surprise. The first enzyme that destroys it was described in 1940, before most people had received a dose. The history since then is a chain of drugs, adaptations and new drugs.
From the book PenicillinChapters 22 to 25. Read the full book free as a PDF.
1940: the enzyme, before the drug was common
Beta-lactamases are enzymes that cleave the beta-lactam ring in penicillins, cephalosporins, monobactams and carbapenems. Abraham and Chain first described them in 1940. The CDC notes that these enzymes are ancient and theorised to have evolved one to two billion years ago.
What Fleming said in 1945
In his Nobel lecture Fleming said it is not difficult to make microbes resistant to penicillin in the laboratory by exposing them to concentrations not sufficient to kill them, and that the same thing has occasionally happened in the body. He warned that when penicillin could be bought by anyone in the shops, an ignorant man could easily underdose himself and, by exposing his microbes to non-lethal quantities, make them resistant. That is the stewardship argument, stated in the year penicillin became a civilian drug.
Hospitals select the enzyme producers
Penicillinase-producing Staphylococcus aureus emerged almost as soon as penicillin was first used. The CDC describes how the spread of penicillin-resistant staphylococci in hospitals in the 1950s showed how penicillin use could select producers of the enzyme from a population of non-producers. A drug that kills the susceptible leaves the resistant to take their place.
Redesign the drug: methicillin, 1959
Methicillin, a semi-synthetic penicillin, was introduced in 1959 to treat penicillinase-producing staphylococci. The chemistry was a modified side chain on the same core, which is the usual form of a response: change the molecule so the enzyme no longer fits.
1961: MRSA, a different answer
In 1961 Margaret Patricia Jevons of the Public Health Laboratory Service in Colindale, London, published the first description of methicillin-resistant Staphylococcus aureus. Barry Cookson, writing fifty years later in The Lancet, called the discovery serendipitous. It was disputed in the early 1960s. The focus then was on severe infections caused by penicillin-resistant 80/81 strains, and some proposed that the heterogeneous resistance was irrelevant and cephalosporins could treat MRSA. It soon became clear that these strains were genuinely resistant, through a new mechanism, and in the 1960s MRSA caused serious problems in many European countries.
The new mechanism involves the target. A review of beta-lactam chemistry names PBP2a from S. aureus as a beta-lactam-resistant penicillin-binding protein that contributes to the MRSA phenotype. This is the other face of how penicillin kills bacteria: if the wall-building enzyme resists the drug, the drug has no foothold.
The toolkit bacteria use
The same review says thousands of different beta-lactamases have been identified, grouped into a few classes. The serine beta-lactamases are classes A, C and D in the Ambler system, and they use a two-step mechanism with a nucleophilic serine. The metallo-beta-lactamases form class B. Some PBPs also slowly hydrolyse the drug complex. PBP5 from Pseudomonas aeruginosa does so for several beta-lactams. Beta-lactamases are the most important resistance mechanism in Gram-negative bacteria.
Chemists answered with inhibitors. Clavulanic acid, the first clinically used beta-lactamase inhibitor, itself contains a beta-lactam ring that acylates the enzyme's serine. Later inhibitors such as avibactam do not contain a beta-lactam ring and react reversibly with the serine.
Where things stand
The World Health Organization estimated that bacterial antimicrobial resistance was associated with more than 4.7 million deaths worldwide in 2021. About one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotic treatment in 2023. Between 2018 and 2023, resistance rose in over 40 percent of the pathogen-antibiotic combinations monitored, by an average of 5 to 15 percent a year. The WHO names misuse and overuse of antibiotics as a main driver, and projects that treating resistant bacterial infections alone could cost US$ 412 billion a year up to 2035, with US$ 443 billion a year in lost productivity, if current levels of action continue.
The pattern holds from 1940 to now: drug, selection, redesign, selection again. It works only while there are new drugs to redesign, a limit explored in the history of antibiotics.
Quick answers
When did penicillin resistance first appear?
The enzyme beta-lactamase, which destroys penicillin, was first described by Abraham and Chain in 1940. Penicillin-resistant staphylococci emerged almost as soon as the drug was in use and spread in hospitals in the 1950s.
What is MRSA?
Methicillin-resistant Staphylococcus aureus. Margaret Jevons published the first description in 1961, two years after methicillin was introduced.
How common is antibiotic resistance now?
The WHO reports that about one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotics in 2023.
Did Fleming warn about resistance?
Yes. In his 1945 Nobel lecture he warned that people who underdose themselves with penicillin could expose their microbes to non-lethal quantities and make them resistant.
Sources
- CDC Emerging Infectious Diseases, "Etymologia: beta-Lactamase" (2016)
- Alexander Fleming, Nobel Lecture, 11 December 1945 (PDF)
- Cookson B., "Five decades of MRSA: controversy and uncertainty continues", The Lancet (2011)
- PMC, review of beta-lactam antibiotics, penicillin-binding proteins and beta-lactamases (PMC8528271)
- World Health Organization, Antimicrobial resistance fact sheet (updated 16 July 2026)
